Back to Search Start Over

Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.

Authors :
Sunati Sahoo
Krings, Gregor
Yunn-Yi Chen
Carter, Jodi M.
Beiyun Chen
Hua Guo
Hanina Hibshoosh
Reisenbichler, Emily
Fang Fan
Shi Wei
Khazai, Laila
Balassanian, Ronald
Klein, Molly E.
Shad, Sonal
Venters, Sara J.
Borowsky, Alexander D.
Symmans, W. Fraser
Tolgay Ocal, I.
Source :
Archives of Pathology & Laboratory Medicine. May2023, Vol. 147 Issue 5, p591-603. 13p. 4 Color Photographs, 1 Diagram, 4 Charts.
Publication Year :
2023

Abstract

Context.-- Neoadjuvant systemic therapy refers to the use of systemic agent(s) for malignancy prior to surgical treatment and has recently emerged as an option for most breast cancer patients eligible for adjuvant systemic therapy. Consequently, treated breast carcinomas have become routine specimens in pathology practices. A standard protocol has not yet been universally adopted for the evaluation and reporting of these specimens. The American Joint Committee on Cancer staging system recognizes the challenges in staging breast carcinomas after neoadjuvant treatment and provides important data points but does not currently provide detailed guidance in estimating the residual tumor burden in the breast and lymph nodes. The Residual Cancer Burden system is the only Web-based system that quantifies treatment response as a continuous variable using residual tumor burden in the breast and the lymph nodes. Objective.-- To provide clarifications and guidance for evaluation and reporting of postneoadjuvant breast specimens, discuss issues with the current staging and reporting systems, and provide specific suggestions for future modifications to the American Joint Committee on Cancer system and the Residual Cancer Burden calculator. Data sources.-- English-language literature on the subject and the data from the I-SPY 2, a multicenter, adaptive randomization phase 2 neoadjuvant platform trial for early-stage, high-risk breast cancer patients. Conclusions.-- This article highlights challenges in the pathologic evaluation and reporting of treated breast carcinomas and provides recommendations and clarifications for pathologists and clinicians. It also provides specific recommendations for staging and discusses future directions. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00039985
Volume :
147
Issue :
5
Database :
Academic Search Index
Journal :
Archives of Pathology & Laboratory Medicine
Publication Type :
Academic Journal
Accession number :
163658453
Full Text :
https://doi.org/10.5858/arpa.2022-0021-EP